Patent US5028593A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5028593A Expired / Lapsed US ⏱️ 0.0 years remaining

Tuftsin analogs

Assignee: The University of Texas System
•
Filing: 1989-08-15
•
Granted: 1991-07-02
•
Expires: 2009-08-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The tuftsin analog Thr-Lys-Leu-Lys has been found to have biological activity superior to that of tuftsin itself.

Inventors

  • 👤 Kenji Nishioka

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 19:57
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/10; C07K5/1002; C07K5/1005; C07K5/1013; A; A61; A61P; A61P31/00; A61P31/04; A61P31/12; A61P31/14; A61P31/18; A61P35/00; A61P37/00; A61P37/02; A61P37/04; C07K16/00; C07K16/06; C07K16/065; A61K; A61K38/00

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 13 words
A peptide having the amino acid sequence Thr-Lys-Leu-Lys and pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim 13 words
A peptide having the amino acid sequence Thr-Lys-Leu-Lys and pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim 13 words
A peptide having the amino acid sequence L-Thr-L-Lys-L-Leu-L-Lys and pharmaceutically acceptable salts thereof.
Claim 4
Dependent Claim 13 words
A peptide having the amino acid sequence L-Thr-L-Lys-L-Leu-L-Lys and pharmaceutically acceptable salts thereof.
Claim 5
Dependent Claim 29 words
A pharmaceutically composition, including: (a) a pharmaceutically effective amount of a peptide having the amino acid sequence Thr-Lys-Leu-Lys and pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim 29 words
A pharmaceutically composition, including: (a) a pharmaceutically effective amount of a peptide having the amino acid sequence Thr-Lys-Leu-Lys and pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim 12 words
The composition of claim 3, where the peptide has the sequence L-Thr-L-Lys-L-Leu-L-Lys.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-07-01 1994-12-31 1995-07-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-07-01 1998-12-31 1999-07-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-07-01 2002-12-31 2003-07-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag